"We formalized our intention in the form of a signed agreement on the production and supply of a vaccine developed by AstraZeneca and Oxford University, using R-Pharm’s technological capabilities to implement the project. Moreover, R-Pharm will act as a kind of hub for vaccine supplies to a huge number of countries — to 30-50 countries, including the Middle East, including Southeast Asia, Europe, naturally the CIS, and naturally Russia ... Naturally, Russia is always a top priority for us," Repik told the Rossiya 24 broadcaster.